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Background:  Recently, the measurement of glycated hemoglobin (HbA1c) was recommended as an alternative to fasting plas-
ma glucose or oral glucose tolerance tests for diagnosing diabetes mellitus (DM). In this study, we analyzed HbA1c levels for dia-
betes mellitus screening in a Korean rural population.
Methods:  We analyzed data from 10,111 subjects from a Korean Rural Genomic Cohort study and generated a receiver operat-
ing characteristic curve to determine an appropriate HbA1c cutoff value for diabetes.
Results:  The mean age of the subjects was 56.3±8.1 years. Fasting plasma glucose and 2-hour plasma glucose after 75 g oral glu-
cose tolerance tests were 97.5±25.6 and 138.3±67.1 mg/dL, respectively. The mean HbA1c level of the subjects was 5.7±0.9%. 
There were 8,809 non-DM patients (87.1%) and 1,302 DM patients (12.9%). A positive relationship between HbA1c and plasma 
glucose levels and between HbA1c and 2-hour plasma glucose levels after oral glucose tolerance tests was found in a scatter plot 
of the data. Using Youden’s index, the proper cutoff level of HbA1c for diabetes mellitus screening was 5.95% (sensitivity, 77%; 
specificity, 89.4%).
Conclusion:  Our results suggest that the optimal HbA1c level for DM screening is 5.95%.
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INTRODUCTION
The prevalence of diabetes is increasing worldwide. In many 
cases, chronic complications in the advanced stage are found 
during diagnosis [1]. In addition, cases of microvascular and 
macrovascular complications have been found in pre-diabetes 
such as impaired fasting glucose or impaired glucose tolerance 
[2]. Early detection and active treatment can help in prevent-
ing the progression of complications and are therefore consid-
ered to be very important for controlling diabetes mellitus.
  Until now, oral glucose tolerance tests have been used to 
measure fasting or postprandial blood glucose in the diagnosis 
of diabetes. However, short-term blood glucose observations 
require fasting prior to blood sampling which can be uncom-
fortable for patients. In addition, since blood sugar levels can 
be affected by exercise, diet, and illness, the patient’s condition, 
and also the temperature at which blood samples are stored at, 
can make the interpretation of results difficult. Therefore, many 
studies have investigated the diagnosis of diabetes using gly-
cated hemoglobin (HbA1c) because more accurate tests and 
simple diagnostic criteria are required for screening of diabe-
tes. The glycated hemoglobin test measures how much glucose 
is bound to hemoglobin in red blood cells. The test reflects the 
level of glucose control over the previous 2 to 3 months and is 
used as an indicator for the risk of complications in patients 
diagnosed with diabetes [3]. In addition, this method is not af-
fected by diet and can be performed at any time; thus, the level 
of glycated hemoglobin in patients who have diabetes can be 
used to determine blood glucose levels more accurately than 
existing tests for the diagnosis of diabetes. Despite its accuracy, 
however, the glycated hemoglobin test has not been consid-
ered reliable due to a lack of standardization. Therefore, it has 
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not been included in the diagnostic criteria for diabetes [4]. 
However, in many recent studies, when glycated hemoglobin 
is compared with fasting blood glucose, it does not fall behind 
the other diabetes screening methods and is considered a use-
ful part of the diagnostic criteria [5]. In addition, as the mea-
suring process for glycated hemoglobin has become more ac-
curate and standardized, the American Diabetes Association 
(ADA) in 2010 adopted glycated hemoglobin level over 6.5% 
as a new diagnostic criteria for diabetes [6]. However, there is 
still controversy over whether this glycated hemoglobin level 
is applicable to Korean adults suitably. Therefore, in this study, 
the glycated hemoglobin levels of patients who received 75 g 
oral glucose tolerance tests were comparatively analyzed in or-
der to determine the appropriate glycated hemoglobin levels 
for screening or diagnosis of diabetes in Korean adults.
METHODS
Between January 2005 and January 2007, this study was per-
formed on 10,111 patients who belonged to the Korean Ge-
nomic Research Cohort. Data on age, gender, blood pressure, 
and body mass index (BMI), calculated by dividing body weight 
(kg) by height squared (m
2), were collected for the all patients. 
Cholesterol, triglycerides, high density lipoprotein cholesterol 
(HDL-C) and low density lipoprotein cholesterol (LDL-C), 
liver enzymes, fasting blood glucose, 75 g oral glucose toler-
ance tests, 2-hour blood glucose samples, and glycated hemo-
globin were investigated. Glycated hemoglobin was measured 
using a high-performance liquid chromatography (HPLC) 
Variant II Turbo (Bio-Rad, Hercules, CA, USA). Using a spe-
cific standardized measurement set established through the 
National Glycohemoglobin Standardization Program (NGSP), 
calibrations were made and the coefficient of variation was be-
tween 1.3% (normal) and 0.8% (abnormal).
  Using Youden’s index, the distribution curve and the rela-
tive character curve for the levels of glycated hemoglobin of 
patients diagnosed with diabetes were generated and used to 
obtain glycated hemoglobin values showing the appropriate 
sensitivity and specificity were investigated. Diabetes was de-
fined as an 8-hour fasting blood glucose over 126 mg/dL and a 
75 g oral glucose tolerance test over 200 mg/dL after 2 hours 
based on criteria set by the Korean Diabetes Association [7].
  Statistical analysis was performed using SPSS program ver-
sion 12.0 for Windows (SPSS Inc., Chicago, IL, USA). Statisti-
cal values were expressed as mean±standard deviation. Thresh-
old values for glycated hemoglobin obtained from the analysis 
of relative characteristic curves were used to predict diabetes.
RESULTS
Clinical characteristics of study participants
The mean age of the patients in this study was 56.3±8.1 years, 
and the gender distribution was 4,091 (40.5%) males and 6,020 
(59.5%) females. The mean fasting level of blood glucose was 
97.5±25.6 mg/dL, and the mean blood glucose level measured 
by 75 g oral glucose tolerance test after 2 hours was 138.3±67.1 
mg/dL. The mean glycated hemoglobin value for all the pa-
tients was 5.7±0.9% (Table 1). The mean glycated hemoglobin 
for males and females were 5.7±0.9% and 5.7±0.8%, respec-
tively, a statistically significant result (P=0.017).
Evaluation of cutoff value (threshold) 
According to the results from fasting plasma glucose and 75 g 
oral glucose tolerance tests, 8,809 (87.1%) of the patients be-
longed to the non-diabetes group. Among them, 1,850 (18.3%) 
Table 1. Clinical characteristics of the subjects
Characteristic Mean±SD 
(n=10,111)
IQR
Age, yr 56.3±8.1
Waist circumference, cm 83.5±8.7 78.0-89.5
BMI, kg/m
2 24.6±3.6 22.4-26.4
SBP, mm Hg 131±18 120-142
DBP, mm Hg 83±13 75-90
Total cholesterol, mg/dL 203.2±39.0 176.0-226.3
Triglyceride, mg/dL 154.5±108.6 88.0-186.0
HDL-C, mg/dL 46.0±11.2 38.0-52.0
LDL-C, mg/dL 119.1±33.3 96.0-140.0
ALT, IU/L 25.9±19.4 17.0-29.0
AST, IU/L 28.8±24.5 21.0-30.0
GGT, IU/L 37.7±79.2 13.0-46.0
Fasting plasma glucose, mg/dL 97.5±25.6 86.0-100.0
2-hr plasma glucose, mg/dL 138.3±67.1 81.0-147.0
Fasting insulin, mU/L 8.7±5.5 5.9-9.8
HbA1c, % 5.7±0.9 5.2-5.8
SD, standard deviation; IQR, inter quartile range; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density li-
poprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, gamma-glutamyl transferase.39
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had impaired fasting glucose and 1,951 (19.3%) had impaired 
glucose tolerance. 1,302 (12.9%) of the patients belonged to 
the diabetes group. The distribution of fasting plasma glucose 
and glycated hemoglobin, and the distribution of glycated he-
moglobin measured from blood glucose after 2-hour 75 g oral 
glucose tolerance tests all showed a positive correlation (Fig. 1). 
When glycated hemoglobin levels used to predict diabetes 
were analyzed using a relative characteristic curve, the sensi-
tivity and specificity were 77.0% and 89.4%, respectively, and 
appropriate levels for selection criteria were observed (Fig. 2).
  This study was a cross-sectional analysis. We did not inves-
tigate diabetic microvascular complications, and providing 
suggestions for diagnostic criteria was difficult. However, with 
results that showed a specificity of 97.5% and a corresponding 
glycated hemoglobin value of 6.4% (Table 2), both of which 
are appropriate values, we believe that this study can be used 
as an indicator for predicting diabetes. 
DISCUSSION
The glycated hemoglobin value reflects glycemic control over 
the previous 2 to 3 months, and there is a positive correlation 
Fig. 2. Receiver operating characteristic curves for HbA1c 
corresponding diabetes mellitus defined by Korean Diabetes 
Association (use Youden’s index).
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Fig. 1. (A) Scatter plot of individuals according to HbA1c and fasting plasma glucose level (correlation coefficient, 0.51; P=0.00) 
(B) Scatter plot of individuals according to HbA1c and 2-hour plasma glucose level after oral glucose tolerance tests (correlation 
coefficient, 0.33; P=0.00). Glu_FBS, fasting blood glucose; Glu_PP120, postprandial blood glucose after 120 minutes.
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Table 2. Comparison of sensitivity and specificity at various 
levels of HbA1c
HbA1c, % Sensitivity, % Specificity, %
5.75 84.1 78.6
5.85 80.1 84.8
5.95 77.0 89.4
6.05 73.9 92.4
6.15 70.7 94.5
6.25 66.6 96.1
6.35 63.4 97.1
6.45 59.4 97.8
6.55 55.5 98.3
6.65 51.8 98.640
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between fasting plasma glucose and blood glucose after 2 hours 
in 75 g oral glucose tolerance test. In addition, glycated hemo-
globin measurements are more reproducible than fasting blood 
glucose, and the coefficient of variation within the population 
is 1.7% compared to 5.7% for fasting blood glucose [8,9]. Fur-
thermore, in the study results from the Diabetes Control and 
Complication Trial (DCCT) and the United Kingdom Pro-
spective Diabetes Study (UKPDS), the authors noted that 
measuring glycated hemoglobin was a useful indicator in pre-
dicting the occurrence of complications with diabetes [10,11]. 
Thus, glycated hemoglobin measurements are measurements 
are receiving spotlights in screening and diagnosing diabetes 
recently. Studies that compare the existing tests to glycated he-
moglobin measurement are being developed and being as-
sessed for their usefulness. In a study of 4,935 participants in 
the U.S. National Health and Nutrition Examination Survey 
(NHANES) for 6 years (1999 to 2004), fasting blood glucose 
was used for the diagnosis of diabetes. On the basis of this 
study, the suggested ranges for glycated hemoglobin are as fol-
lows: over 5.8% indicates impaired glucose metabolism, 6.1% 
to 6.9% is considered to be pre-diabetes, and over 7% is con-
sidered to be diabetes [12]. In addition, several studies have 
reported a relationship between glycated hemoglobin and dia-
betic retinopathy [13,14], and in 2010, through NGSP stan-
dardization [15], the ADA proposed that glycated hemoglobin 
levels greater than 6.5% should be diagnosed as diabetes [6]. 
In the 2002 Japan National Diabetes survey based on impaired 
glucose metabolism, glycated hemoglobin greater than 6.1% is 
classified as probable DM, 5.6% to 6.0% as possible DM, and 
less than 5.6% as normal [16].
  There have been many recent studies in Korea regarding the 
use of glycated hemoglobin levels for the diagnosis of diabetes. 
Kim et al. [17] performed a study on 205 patients with normal 
fasting blood glucose who had never been diagnosed with glu-
cose metabolism impairments. Among those patients, the mean 
glycated hemoglobin value between the diabetes group and the 
non-diabetes group was 6.1±0.7% and 5.7±0.5%, respectively, 
a statistically significant difference. In addition, this study re-
ported that diabetes could be predicted through glycated he-
moglobin measurements. In a study based on fasting blood 
glucose performed by Ku et al. [18] on 19,178 patients who did 
not have diabetes, the threshold glycated hemoglobin value for 
predicting diabetes was 5.9%. In addition, using a 2-hour oral 
glucose tolerance test with the threshold value set at 6.1% for 
glycated hemoglobin, sensitivities and specificities were 
84.6%/85.9% and 86.5%/85.8%, respectively. In a study by Bae 
et al. [19] performed on 1,482 patients who had not previously 
been diagnosed with diabetes, the glycated hemoglobin thresh-
old value for predicting diabetes was set at 5.95%, and the sen-
sitivity and specificity were reported to be 60.8% and 85.6%, 
respectively. In a retrospective study by Jung et al. [20] per-
formed on 1,474 diabetes patients, a glycated hemoglobin 
threshold value of 6.75% and a specificity of 85% were sug-
gested for the diagnosis of diabetes. In our study results, the 
glycated hemoglobin threshold was 5.95%. However, the spec-
ificity must be higher in order for glycated hemoglobin to be 
used as a diagnostic criteria [21]; therefore, the baseline for 
predicting diabetes was set at 6.4%, which corresponds to the 
specificity of 97.5%. This baseline prediction value is used in 
many studies, and when used for the diagnosis of diabetes, the 
specificity value is considered to be high [22-26].
  However, there are several problems when glycated hemo-
globin is used for the prediction of diabetes in Korean adults, 
primarily because the measurement of glycated hemoglobin 
has not yet been standardized in Korea. As a result, the differ-
ences between compared measurements cause many difficul-
ties in the analysis of the results. Standards must be preceded 
by selection criteria or by diagnostic criteria.
  In addition, Korean diets are different from Western diets, 
and this can result in a difference in blood glucose after meals 
which can also influence glycated hemoglobin. According to the 
2008 National Health Statistics [27], the daily consumption of 
carbohydrates for Koreans is 293.3 g. According to the 2006 U.S. 
National Health and Nutrition Examination Survey [28], Amer-
icans consume an average of 265 g of carbohydrates per day. 
Thus, Koreans may have higher blood glucose levels after meals 
compared to Americans. In addition, Korean diabetics have 
fewer beta cells compared to American diabetics, and there are 
studies regarding the amount of insulin secreted after meals 
[29]. Other factors that may cause differences between Korean 
and American diabetics include culture and socio-economic 
differences, susceptibility to diabetes, enzymatic activity, and in-
tracellular accumulations of glycated hemoglobin resulting 
from varying degrees of non-enzymatic glycosylation [30,31].
  The threshold value of 5.95% for glycated hemoglobin set 
by the authors of this study was not significantly different from 
previous studies. However, African Americans consistently 
showed higher glycated hemoglobin than other races in stud-
ies performed by Saudek et al. [2] and Selvin et al. [32], and 
this was also true in the normal fasting blood glucose state. 41
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Such racial difference is caused by the use of glycated hemo-
globin as a diagnostic criterion; therefore, the use of this meth-
od for the diagnosis of diabetes may be problematic. Also, be-
cause glycated hemoglobin is measured directly from red blood 
cells, factors affecting the survival of red blood cells such as 
hemolytic anemia, aplastic anemia, hemorrhage, and splenec-
tomy may disrupt the normal relationship between blood glu-
cose and glycated hemoglobin. Hemolytic anemia and acute 
hemorrhaging may cause glycated hemoglobin to drop, and 
patients with aplastic anemia or who have received splenecto-
my have older red blood cells; therefore, regardless of blood 
glucose concentrations, glycated hemoglobin concentrations 
may increase [2]. Additionally, high doses of salicylate or vita-
min C, and deficiencies of vitamin E or iron may also affect 
glycated hemoglobin [2].
  Because of these problems, appropriate glycated hemoglo-
bin values have not been established for the diagnostic criteria 
of diabetes in Koreans; however, this topic is still considered 
controversial. Despite the problems associated with using gly-
cated hemoglobin, there are many benefits of using it for the 
diagnosis and prediction of diabetes and its complications 
compared to the existing tests. Therefore, we believe glycated 
hemoglobin will play a large role in the diagnosis of diabetes 
in the future. However, more research regarding the effects of 
racial differences and other factors on glycated hemoglobin is 
needed in order for it to become more widely used in the diag-
nosis of diabetes. 
  This study has the following limitations. First, the cohort 
data was collected from individuals living in rural communi-
ties, so regional lifestyle differences may have influenced the 
results. Second, the greater number of females than males in 
this study may have also influenced the results. Because of the 
limitations of the glycated hemoglobin test, large-scale prospec-
tive studies using supplemental varied data will be required in 
the future. Furthermore, additional studies on threshold for 
increased occurrence of diabetes-associated microvascular 
complications will be needed to obtain a more precise diabetes 
diagnostic criterion. 
  In this study, the appropriate levels of glycated hemoglobin 
were evaluated for the screening and diagnosis of diabetes. Us-
ing a relativity curve, the threshold value for glycated hemo-
globin was 5.95%, and the sensitivity and specificity for the se-
lection criteria were 77% and 89.4%, respectively. Also, the 
corresponding specificity of 97.5% for a glycated hemoglobin 
value of 6.4% was considered appropriate for diagnostic pre-
dictions. On the basis of this study, glycated hemoglobin should 
be considered as a method that can replace or complement ex-
isting screening methods for the diagnosis of diabetes.
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